

## **RECORDATI: SUMMARY REPORT OF THE VOTES - ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 21.04.2023**

Milan, 21<sup>st</sup> April 2023 – Please be informed that the summary report of the voting results related to the resolutions approved by the Ordinary General Meeting of the Shareholders on 21<sup>st</sup> April 2023, pursuant to article 125-quater of the Legislative Decree 58/98, is available to the public on the Company's website ([www.recordati.it](http://www.recordati.it), in the area "Investors", section "Shareholders' Meetings") and on the "1info" storage mechanism ([www.1info.it](http://www.1info.it)).

***Recordati** (Reuters RECI.MI, Bloomberg REC IM), established in 1926, is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and other countries of the CIS, Ukraine, Turkey, North Africa, the United States, Canada, Mexico, some South American countries, Japan, Australia and New Zealand, China and South Korea. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under licence, from a number of therapeutic areas, including a global specialised business, dedicated to rare diseases. Recordati is a partner of choice for new product licences for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2022 was € 1,853.3 million, operating income was € 437.3 million and net income was € 312.3 million.*

For further information:

Recordati website: [www.recordati.it](http://www.recordati.it)

Investor Relations

Federica De Medici

(39) 02 48787146

e-mail: [investorelations@recordati.it](mailto:investorelations@recordati.it)

Investor Relations

Lucia Abbatantuoni

(39) 02 48787213

e-mail: [investorelations@recordati.it](mailto:investorelations@recordati.it)

Media Relations

Brunswick: Barbara Scalchi / Andrea Mormandi

(39) 02 9288 6200

e-mail: [recordati@brunswickgroup.com](mailto:recordati@brunswickgroup.com)

### **RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.**

Registered Office

Via Matteo Civitali, 1

20148 Milano, Italy

Ph. (39) 02 487871

Fax (39) 02 40073747

[www.recordati.com](http://www.recordati.com)

Share Capital € 26.140.644,50 fully paid-up

Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150

Tax Code/VAT No. 00748210150

Milano R.E.A. No. 401832

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.à.r.l